Glomerulonephritis in Two Patients with SpA Treated with TNF-α Blockers and a Review of the Literature

References

• Stokes MB, Foster K, Markowitz GS, et al. Development of glomerulonephritis during anti-TNF-alpha; therapy for rheumatoid arthritis. Nephrol Dial Transplant. 2005;20:1400–1406. doi:10.1093/ndt/gfh832
   PubMed Web of Science ®Google Scholar
• Ayaash A, Maan D, Kapetanos A, Bunker M, Wasko MC, Clark B. Significance of crescentic glomeruli in acute kidney injury with rheumatoid arthritis. Case Reports Nephrol Dial. 2019;9:42–48. doi:10.1159/000500105
   Web of Science ®Google Scholar
• Premužić V, Padjen I, Cerovec M, Ćorić M, Jelaković B, Anić B. The association of TNF-alpha inhibitors and development of IgA nephropathy in patients with rheumatoid arthritis and diabetes. Case Rep Nephrol. 2020.
   Google Scholar
• Morgane V, Jean-Charles C, Nicolas M, et al. Renal sarcoid-like granulomatosis during anti-TNF therapy. Kidney Int. 2014;86:215. doi:10.1038/ki.2013.452
   Web of Science ®Google Scholar
• Ramos-Casals M, Brito-Zerón P, Soto MJ, Cuadrado MJ, Khamashta MA. Autoimmune diseases induced by TNF-targeted therapies. Best Pract Res Clin Rheumatol. 2008;22:847–861. doi:10.1016/j.berh.2008.09.008
   PubMed Web of Science ®Google Scholar
• Piga M, Chessa E, Ibba V, et al. Biologics-induced autoimmune renal disorders in chronic inflammatory rheumatic diseases: systematic literature review and analysis of a monocentric cohort. Autoimmun Rev. 2014;13:873–879. doi:10.1016/j.autrev.2014.05.005
   PubMed Web of Science ®Google Scholar
• Davide D, Marta P, Antonella B, et al. Double glomerulonephritis in a patient with ankylosing spondylitis treated with biologic agent: extrarticolar involvement or anti-tumor necrosis factor alpha injury? A case-based review. Clin Med Insights Case Rep. 2020;13. doi:10.1177/1179547620974672
   Web of Science ®Google Scholar
• Rolle AS, Zimmermann B, Poon SH. Etanercept-induced henoch-schönlein purpura in a patient with ankylosing spondylitis. J Clin Rheumatol. 2013;19:90–93. doi:10.1097/RHU.0b013e3182863027
   Web of Science ®Google Scholar
• Kaushik P, Rahmani M, Ellison W. Membranous glomerulonephritis with the use of etanercept in ankylosing spondylitis. Ann Pharmacother. 2011;45:1585. doi:10.1345/aph.1Q492
   Google Scholar
• Jacquet A, Francois H, Frangie C, et al. IgA nephropathy associated with ankylosing spondylitis is not controlled by infliximab therapy. Nephrol Dial Transplant. 2009;24:3540–3542. doi:10.1093/ndt/gfp314
   Web of Science ®Google Scholar
• Korsten P, Sweiss NJ, Nagorsnik U, et al. Drug-induced granulomatous interstitial nephritis in a patient with ankylosing spondylitis during therapy with adalimumab. Am J Kidney Dis. 2010;56:e17–e21. doi:10.1053/j.ajkd.2010.08.019
   PubMed Web of Science ®Google Scholar
• Yarkan Tuğsal H, Zengin B, Kenar G, et al. Infliximab-associated focal segmental glomerulosclerosis in a patient with ankylosing spondylitis. Rheumatol Int. 2019;39:561–567. doi:10.1007/s00296-019-04241-8
   Web of Science ®Google Scholar
• Tosovský M, Bradna P, Laco J, Podhola M, Soukup T, Brozík J. Case 1-2012: ANCA associated glomerulonephritis in combination with IgG4-positive mediastinal mass in a patient with ankylosing spondylitis treated with TNF alpha inhibitors. Acta Medica (Hradec Kralove). 2012;55:42–46. doi:10.14712/18059694.2015.74
   Google Scholar
• Lee A, Kasama R, Evangelisto A, Elfenbein B, Falasca G. Henoch-Schönlein purpura after etanercept therapy for psoriasis. J Clin Rheumatol. 2006;12:249–251. doi:10.1097/01.rhu.0000239901.34561.5e
   PubMed Web of Science ®Google Scholar
• Strobel ES, Fritschka E. Renal diseases in ankylosing spondylitis: review of the literature illustrated by case reports. Clin Rheumatol. 1998;17:524–530. doi:10.1007/BF01451293
   Web of Science ®Google Scholar
• El Maghraoui A. Extra-articular manifestations of ankylosing spondylitis: prevalence, characteristics and therapeutic implications. Eur J Intern Med. 2011;22:554–560. doi:10.1016/j.ejim.2011.06.006
   PubMed Web of Science ®Google Scholar
• Ben Taarit C, Ajlani H, Ben Moussa F, Ben Abdallah T, Ben Maïz H, Khedher A. Renal involvement in ankylosing spondylitis: concerning 210 cases. Rev Med Interne. 2005;26:966–969. doi:10.1016/j.revmed.2005.07.017
   Web of Science ®Google Scholar
• Levy AR, Szabo SM, Rao SR, Cifaldi M, Maksymowych WP. Estimating the occurrence of renal complications among persons with ankylosing spondylitis. Arthritis Care Res. 2014;66:440–445. doi:10.1002/acr.22176
   Web of Science ®Google Scholar
• Champtiaux N, Lioté F, El Karoui K, et al. Spondyloarthritis-associated IgA nephropathy. Kidney Int Rep. 2020;5:813–820. doi:10.1016/j.ekir.2020.03.012
   Web of Science ®Google Scholar
• Lim SJ, Lee EJ, Chung SW, et al. Renal involvement in ankylosing spondylitis: prevalence, pathology, response to TNF-a blocker. Rheumatol Int. 2013;33:1689–1692. doi:10.1007/s00296-012-2624-9
   Web of Science ®Google Scholar
• Couderc M, Pereira B, Molto A, Tiple A, Soubrier M, Dougados M. The prevalence of renal impairment in patients with spondyloarthritis: results from the international ASAS-COMOSPA study. J Rheumatol. 2018;45:795–801. doi:10.3899/jrheum.170133
   PubMed Web of Science ®Google Scholar
• Kobak S, Oksel F, Kabasakal Y, Doganavsargil E. Ankylosing spondylitis-related secondary amyloidosis responded well to etanercept: a report of three patients. Clin Rheumatol. 2007;26:2191–2194. doi:10.1007/s10067-007-0679-x
   PubMed Web of Science ®Google Scholar
• Sakellariou GT, Vounotrypidis P, Berberidis C. Infliximab treatment in two patients with psoriatic arthritis and secondary IgA nephropathy. Clin Rheumatol. 2007;26:1132–1133. doi:10.1007/s10067-006-0422-z
   Web of Science ®Google Scholar